Application 761100
- Type
- BLA
- Sponsor
- SAMSUNG BIOEPIS CO LTD
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | ONTRUZANT | TRASTUZUMAB-DTTB | INJECTABLE;INJECTION | 150MG | No | No |
| 002 | ONTRUZANT | TRASTUZUMAB-DTTB | POWDER;IV (INFUSION) | 420MG | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0006-5033 | Ontruzant | trastuzumab | Merck Sharp & Dohme Corp. | BLA | Current |
| 0006-5033 | Ontruzant | trastuzumab | Merck Sharp & Dohme Corp. | BLA | Current |
| 0006-5034 | Ontruzant | Ontruzant | Merck Sharp & Dohme Corp. | BLA | Current |
| 0006-5034 | Ontruzant | Ontruzant | Merck Sharp & Dohme Corp. | BLA | Current |
| 78206-147 | Ontruzant | trastuzumab | Organon LLC | BLA | Current |
| 78206-148 | Ontruzant | Ontruzant | Organon LLC | BLA | Current |
Documents#
Document, Submission type, Date table| Document | Submission type | Date |
|---|
| 84370 | SUPPL | 2025-12-09 |
| 81493 | SUPPL | 2025-03-07 |
| 81444 | SUPPL | 2025-03-07 |
| 70106 | SUPPL | 2022-02-07 |
| 70103 | SUPPL | 2022-02-07 |
| 57314 | ORIG | 2019-03-07 |
| 57908 | ORIG | 2019-03-05 |
| 57246 | ORIG | 2019-01-18 |